"It is gratifying to see someone whose tumor has been resistant to other therapies do well with this promising investigational therapy. The patient has received NKP-1339 for more than a year and continues to benefit," added Dr. Howard Burris.
"We are pleased by these interim results demonstrating the single agent anti-tumor activity of NKP-1339 in patients with advanced cancers refractory to standard treatments," said Dr. Angela Ogden, Chief Medical Officer for Niiki Pharma Inc.
"The preliminary results of this ongoing trial, showing the anti-tumor activity and the safety profile of NKP-1339, support our preclinical studies that the drug targets tumors selectively and is active against different tumors. We are delighted to see years of research come to fruition in collaboration with Niiki Pharma's team," said Professor Keppler, University of Vienna, inventor of NKP-1339.
About NKP-1339NKP-1339 is a first-in-class transferrin targeted ruthenium-based anti-cancer compound. Transferrin receptor is significantly over-expressed in many tumor types. The intracellular target pathways of NKP-1339 include down-regulation of GRP78, a key regulator of mis-folded protein processing and a tumor survival factor. GRP78 is the cause of resistance in many tumor types. In preclinical studies, NKP-1339 has demonstrated activity against multiple tumor types, including those resistant to other anti-cancer agents, including platinum-containing agents, anthracyclines and anti-tubulins.
NKP-1339 was invented by Professor Bernard K. Keppler, currently the Dean of the Faculty of Chemistry at University of Vienna, Austria, and Head of the Research Platform "Translational Cancer Therapy Research", a multi-disciplinary collaboration between University of Vienna and th
|SOURCE Niiki Pharma Inc.|
Copyright©2010 PR Newswire.
All rights reserved